Latest News and Press Releases
Want to stay updated on the latest news?
-
Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean...
-
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand...
-
Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 –...
-
Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
-
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development...
-
Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL)...
-
Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or...
-
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational...
-
Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq...
-
Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b...